TITLE

Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures

AUTHOR(S)
Deng, Wei-min; Zhang, Peng; Huang, Hai; Shen, You-gao; Yang, Qin-hua; Cui, Wei-li; He, Yang-shu; Wei, Song; Ye, Zhu; Liu, Fang; Qin, Ling
PUB. DATE
September 2012
SOURCE
Journal of Bone & Mineral Metabolism;Sep2012, Vol. 30 Issue 5, p517
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To observe the kidney-tonifying herbal Fufangs with phytoestrogenic epimedium for prevention of postmenopausal osteoporosis with both bone mineral density (BMD) and fracture as study endpoints, a 5-year multicenter follow-up study in 194 postmenopausal women (47-70 years old) was conducted in which the subjects were given oral administration of herbal Fufang (10 g/day, twice per day, n = 101) or placebo ( n = 93). Both groups were supplemented daily with calcium (600 mg) and vitamin D (400 IU). BMD at distal radius, potential adverse events, and fracture incidence were evaluated at baseline and at 6, 12, 24, 36, 48, and 60 months. At the end of 5 years, 155 subjects had completed the study, with better adherence in the treatment group (13% dropouts, n = 88 at year 5) as compared with the control group (28% dropouts, n = 67 at year 5) ( P < 0.05). No notable adverse events were observed in either group. In the treatment group BMD increased significantly from baseline (0.211 ± 0.022 g/cm) to the end of the study (0.284 ± 0.015 g/cm), whereas the control group decreased significantly from baseline (0.212 ± 0.023 g/cm) to 5 years later (0.187 ± 0.022 g/cm) ( P < 0.05). The fracture incidence was 2.4 fold lower in the treatment group than in the control group, with a relative risk of 0.57 for the treatment group (95% CI, 0.43-0.70, P < 0.05). In conclusion, in addition to the beneficial effects of oral herbal Fufang on prevention of postmenopausal bone loss, this 5-year multi-center clinical study demonstrated for the first time its potential for reduction in fragility fracture incidence.
ACCESSION #
79824419

 

Related Articles

  • Current Treatment Approaches to Osteoporosis--2013. Honig, Stephen; Rajapakse, Chamith S.; Gregory Chang // Bulletin of the Hospital for Joint Diseases;2013, Vol. 71 Issue 3, p184 

    The clinical diagnosis of osteoporosis has evolved over the past 20 years to emphasize the relationship between compromised bone strength and fracture susceptibility. The goal of treatment of osteoporosis is fracture prevention. The aging of the American population will place additional burdens...

  • Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Shimon, Ilan; Eshed, Varda; Doolman, Ram; Sela, Ben-Ami; Karasik, Avraham; Vered, Iris // Osteoporosis International;Dec2005, Vol. 16 Issue 12, p1591 

    Male hypogonadism is associated with low bone mineral density (BMD) and an increased risk of fractures. Testosterone replacement therapy improves BMD in young hypogonadal men. This effect is milder in older patients, who are at greater risk for fractures. We studied the effects of alendronate or...

  • Calcium reduced loss of bone mineral density but did not prevent fractures in healthy postmenopausal women. Riddell, Lenore // Evidence Based Nursing;Apr2007, Vol. 10 Issue 2, p53 

    The article presents information on a medical research about the effectiveness of calcium supplements in reducing loss of bone mineral density and preventing fractures in postmenopausal women. The research involved 1,471 healthy postmenopausal women and used a randomized, placebo controlled...

  • Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis. Ma Chao; Qin Hua; Zhou Yingfeng; Wan Guang; Shi Shufeng; Dong Yuzhen; Wang Wei; Tan Haifeng // Pakistan Journal of Medical Sciences;Nov/Dec2013, Vol. 29 Issue 6, p1381 

    Objective: We aimed to assess the role of zoledronic acid (ZOL) on the risk of fracture and bone mineral density (BMD) in women with osteoporosis. Methods: A double-blind and placebo-controlled design was taken in our study. 327 patients who received an intravenous 5-mg infusion zoledronic acid...

  • BMD Testing: What's the Appropriate Interval? Kuritzky, Louis // Alternative Medicine Alert;Apr2012 Supplement, p48 

    The article focuses on the Study of Osteoporotic Fractures which aimed to establish a baseline for the appropriate interval of bone mineral density (BMD) testing to identify osteoporosis.

  • Denosumab: A new injectable treatment for postmenopausal osteoporosis. Whelan, Anne Marie; Raman-Wilms, Lalitha // Canadian Pharmacists Journal;Mar/Apr2011, Vol. 144 Issue 2, p72 

    The article presents a study which determines the efficacy of the injectable denosumab for the treatment of postmenopausal osteoporosis. The researchers have examined the safety and effect of denosumab on bone mineral density (BMD) in the management of postmenopausal osteoporosis. The study...

  • Adverse Reaction Research.  // Reactions Weekly;12/15/2007, Issue 1182, p4 

    The article discusses the findings of a multicentre, randomised trial which examined the benefit of alendronic acid to paediatric patients at risk for glucocorticoid-induced osteoporosis. The results were presented at the joint annual meeting of the American College of Rheumatology and the...

  • Soy isoflavones fail to prevent bone loss or menopausal symptoms. Brown, Simon // Menopause International;Dec2011, Vol. 17 Issue 4, p117 

    The article focuses on a single-centre randomized placebo-controlled trial regarding the wider use of soy isoflavones in the treatment of postmenopausal women. It notes that a total of 248 women aged 45-60 years who were within five years of the menopause and had a bone mineral density T-score...

  • Prediction of hip and other osteoporotic fractures from hip geometry in a large clinical cohort. Leslie, W. D.; Pahlavan, P. S.; Tsang, J. F.; Lix, L. M. // Osteoporosis International;Oct2009, Vol. 20 Issue 10, p1767 

    Incident hip fractures and non-hip osteoporotic fractures were studied in 30,953 women during mean 3.7 years of observation. Hip axis length (HAL) and strength index (SI) made a small but statistically significant contribution to hip fracture prediction that was independent of age and hip bone...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics